DECIPHER BIOSCIENCES INC has a total of 24 patent applications. It increased the IP activity by 550.0%. Its first patent ever was published in 2012. It filed its patents most often in Australia, EPO (European Patent Office) and Canada. Its main competitors in its focus markets biotechnology, computer technology and measurement are GENOMEDX BIOSCIENCES INC, MULTIPLICOM NV and GENECENTRIC THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 9 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | Canada | 3 | |
#4 | United States | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Computer technology | |
#3 | Measurement | |
#4 | Environmental technology | |
#5 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Davicioni Elai | 24 |
#2 | Erho Nicholas | 14 |
#3 | Zhao Shuang G | 8 |
#4 | Erho Nicholas George | 8 |
#5 | Feng Felix Y | 8 |
#6 | Ashab Hussam Al-Deen | 8 |
#7 | Alshalalfa Mohammed | 6 |
#8 | Chang S Laura | 5 |
#9 | Vergara Correa Ismael A | 4 |
#10 | Lehrer Jonathan | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020231997A1 | Non-cording rna for treatment of bladder cancer | |
CA3062716A1 | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness | |
AU2018230784A1 | Subtyping prostate cancer to predict response to hormone therapy | |
CA3050984A1 | Molecular subtyping, prognosis, and treatment of bladder cancer | |
EP3504348A1 | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy | |
EP2791359A1 | Cancer diagnostics using non-coding transcripts |